CytoMed Therapeutics
GDTC
5 hedge funds and large institutions have $70.8K invested in CytoMed Therapeutics in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
150% more funds holding
Funds holding: 2 → 5 (+3)
96% more capital invested
Capital invested by funds: $36.1K → $70.8K (+$34.7K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$57.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$23K |
| 3 |
SG
StoneX Group
New York
|
+$20.1K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$41 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$23.7K |
| 2 |
WANY
Wealthspire Advisors (New York)
New York
|
-$9.62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $39.7K | +$57.8K | +29,829 | New |
|
|
TSS
2
Two Sigma Securities
New York
| $15.8K | +$23K | +11,857 | New |
|
|
SG
3
StoneX Group
New York
| $13.8K | +$20.1K | +10,356 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $1.42K | -$23.7K | -12,224 | -92% |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $28 | +$41 | +21 | New |
|
|
WANY
6
Wealthspire Advisors (New York)
New York
| – | -$9.62K | -4,835 | Closed |
|
GDTC Hedge Fund Activity: Q4 2025 in Review
5 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q4 2025, worth a combined $70.8K — up 96% from $36.1K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GDTC positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $57.8K. The largest seller was UBS Group, cutting an estimated $23.7K.
- 5 institutional investors held CytoMed Therapeutics (GDTC) as of Q4 2025, up from 2 in Q3 2025.
- Funds reported $70.8K of CytoMed Therapeutics stock for Q4 2025, up 96% quarter-over-quarter.
- 4 funds opened new CytoMed Therapeutics positions in Q4 2025 and 1 closed out, a net change of +3 holders.
- The largest CytoMed Therapeutics buyer in Q4 2025 was Susquehanna International Group, an estimated $57.8K added.
- The largest CytoMed Therapeutics seller in Q4 2025 was UBS Group, an estimated $23.7K sold.
Based on aggregated 13F filings for Q4 2025.